Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases.

CEA CTV GTV PET-CT bispecific antibody immuno-PET radiation oncology stereotactic ablative body radiotherapy (SABR) stereotactic body radiation therapy (SBRT) targeting vertebral metastases

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
28 Nov 2020
Historique:
received: 21 10 2020
revised: 18 11 2020
accepted: 23 11 2020
entrez: 2 12 2020
pubmed: 3 12 2020
medline: 3 12 2020
Statut: epublish

Résumé

(1) Background: Stereotactic body radiotherapy (SBRT) for vertebral metastases (VM) allows the delivery of high radiation doses to tumors while sparing the spinal cord. We report a new approach to clinical target volume (CTV) delineation based on anti-carcinoembryonic antigen (CEA) positron emission tomography (pretargeted immuno-PET; "iPET") in patients with metastatic breast cancer (BC) or medullary thyroid cancer (MTC). (2) Methods: All patients underwent iPET, spine magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) using

Identifiants

pubmed: 33260610
pii: biomedicines8120548
doi: 10.3390/biomedicines8120548
pmc: PMC7760481
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-11-EQPX-0004
Organisme : Agence Nationale de la Recherche
ID : ANR-11-LABX-0018-01
Organisme : Direction Générale de l'offre de Soins
ID : INCa-DGOS-Inserm_12558 (SIRIC ILIAD)
Organisme : Centre Hospitalier Universitaire de Nantes
ID : no grant number

Références

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):840-847
pubmed: 27663759
J Clin Oncol. 2007 Nov 20;25(33):5287-312
pubmed: 17954709
Eur J Radiol. 2012 May;81(5):1007-15
pubmed: 21354739
J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7
pubmed: 17878252
Int J Mol Sci. 2016 Dec 28;18(1):
pubmed: 28036044
J Nucl Med. 2020 Aug;61(8):1205-1211
pubmed: 32169921
Adv Radiat Oncol. 2019 Nov 06;5(2):260-268
pubmed: 32280826
J Nucl Med. 2016 Oct;57(10):1505-1511
pubmed: 27230928
Eur J Nucl Med Mol Imaging. 2020 Aug 21;:
pubmed: 32820369
Br J Radiol. 2019 Nov;92(1103):20190211
pubmed: 31322920
J Nucl Med. 2004 Feb;45(2):279-84
pubmed: 14960648
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e597-605
pubmed: 22608954
Future Oncol. 2017 Jan;13(1):77-91
pubmed: 27523190
Eur Radiol. 2011 Dec;21(12):2604-17
pubmed: 21887484
JAMA Oncol. 2020 Apr 1;6(4):567-577
pubmed: 31895403
Minim Invasive Neurosurg. 2006 Jun;49(3):127-34
pubmed: 16921451
J Neurosurg Spine. 2017 Sep;27(3):295-302
pubmed: 28598293

Auteurs

Baptiste Pichon (B)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.
Department of Radiation Oncology, Clinique Pasteur, 31300 Toulouse, France.

Caroline Rousseau (C)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.
Centre de Recherche en Cancéro-Immunologie Nantes Angers (CRCINA), Inserm U1232, CNRS ERL 6001, Université de Nantes, F-44000 Nantes, France.

Audrey Blanc-Lapierre (A)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.

Gregory Delpon (G)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.
Centre de Recherche en Cancéro-Immunologie Nantes Angers (CRCINA), Inserm U1232, CNRS ERL 6001, Université de Nantes, F-44000 Nantes, France.

Ludovic Ferrer (L)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.
Centre de Recherche en Cancéro-Immunologie Nantes Angers (CRCINA), Inserm U1232, CNRS ERL 6001, Université de Nantes, F-44000 Nantes, France.

Vincent Libois (V)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.

Matthieu Le Turnier (M)

Department of nuclear medicine and radiology, Centre Hospitalier Universitaire, F-44000 Nantes, France.

Cédric Lenoble (C)

Department of nuclear medicine and radiology, Centre Hospitalier Universitaire, F-44000 Nantes, France.

Caroline Bodet-Milin (C)

Centre de Recherche en Cancéro-Immunologie Nantes Angers (CRCINA), Inserm U1232, CNRS ERL 6001, Université de Nantes, F-44000 Nantes, France.
Department of nuclear medicine and radiology, Centre Hospitalier Universitaire, F-44000 Nantes, France.

David M Goldenberg (DM)

Center for Molecular Medicine and Immunology, Mendham, NJ 07945-2704, USA.

Françoise Kraeber-Bodere (F)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.
Centre de Recherche en Cancéro-Immunologie Nantes Angers (CRCINA), Inserm U1232, CNRS ERL 6001, Université de Nantes, F-44000 Nantes, France.
Department of nuclear medicine and radiology, Centre Hospitalier Universitaire, F-44000 Nantes, France.

Stéphane Supiot (S)

Department of Radiotherapy and Nuclear Medicine Institut de Cancérologie de l'Ouest (ICO), F-44800 Saint-Herblain, France.
Centre de Recherche en Cancéro-Immunologie Nantes Angers (CRCINA), Inserm U1232, CNRS ERL 6001, Université de Nantes, F-44000 Nantes, France.

Classifications MeSH